Form 4: Aquestive Therapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
Peter E. Boyd, Chief People Officer of Aquestive Therapeutics, Inc., reported multiple transactions in common stock on September 9, 2026.
Summary
- In-the-money derivative exercise: acquired 2,293 Common Stock at $0.96 ($2,201) on September 9, 2026; holds 284,024 after (Direct).
- In-the-money derivative exercise: disposed of 2,293 Warrant (Right to Buy) on September 9, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Peter E. Boyd — Officer (Chief People Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | In-the-money derivative exercise | Common Stock | 2,293 | $1 | $2.2K | 284,024 |
| 2026-09-09 | In-the-money derivative exercise | Warrant (Right to Buy) | 2,293 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | In-the-money derivative exercise (2,293 shares) |
| 2026-09-09 | In-the-money derivative exercise (2,293 shares) |
Keywords
insider transaction, Form 4, AQST, Aquestive Therapeutics, Inc., neutral, Peter E. Boyd
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.